NCT01305239View on ClinicalTrials.gov

A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients

TerminatedOBSERVATIONAL
Enrollment

398

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Breast Cancer
Interventions
DRUG

Aromasin

Aromasin 25 mg daily.

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01305239 - A Survey Of Clinical Practice Of Adjuvant Treatment Of Breast Cancer Using Exemestane (Aromasin®) In Postmenopausal Hr+ Patients | Biotech Hunter | Biotech Hunter